Publications by authors named "Barbara Volz"

Claim this Profile
M
Mass cytometric detection of homologous recombination proficiency in circulating tumor cells to predict chemoresistance of metastatic breast cancer patients.
Kathrin Niedermayer, Henning Schäffler, Georgios Vlachos, Sara Greco, Kerstin Pfister, Barbara Volz

Int J Cancer· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
CRISPR-Cas9 screen reveals that inhibition of enhancer of zeste homolog 2 sensitizes malignant T cells to dimethyl-fumarate-induced cell death.
Jan P Teubner, Deniz Tümen, Arne Kandulski, Philipp Heumann, Patricia Mester, Barbara Volz

FEBS J· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Microfluidic Isolation of Disseminated Tumor Cells from the Bone Marrow of Breast Cancer Patients.
Léa L Volmer, Cansu E Önder, Barbara Volz, Anjali R Singh, Sara Y Brucker

Int J Mol Sci· September 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
HCC biomarkers - state of the old and outlook to future promising biomarkers and their potential in everyday clinical practice.
Sophie Schlosser, Deniz Tümen, Barbara Volz, Katja Neumeyer, Niklas Egler

Front Oncol· November 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Beneficial modulation of the tumor microenvironment and generation of anti-tumor responses by TLR9 agonist lefitolimod alone and in combination with checkpoint inhibitors.
Kerstin Kapp, Barbara Volz, Detlef Oswald, Burghardt Wittig, Matthias Baumann

Oncoimmunology· September 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
EnanDIM - a novel family of L-nucleotide-protected TLR9 agonists for cancer immunotherapy.
Kerstin Kapp, Barbara Volz, Michael A Curran, Detlef Oswald, Burghardt Wittig

J Immunother Cancer· January 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Design and characterization of the tumor vaccine MGN1601, allogeneic fourfold gene-modified vaccine cells combined with a TLR-9 agonist.
Barbara Volz, Manuel Schmidt, Kerstin Heinrich, Kerstin Kapp, Matthias Schroff

Mol Ther Oncolytics· April 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
MIDGE Technology for the Production of a Fourfold Gene-Modified, Allogenic Cell-Based Vaccine for Cancer Therapy.
Manuel Schmidt, Barbara Volz, Patrick Großmann, Kerstin Heinrich, Burghardt Wittig

Methods Mol Biol· March 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis